Sanders C V, Hanna B J, Lewis A C
Am Rev Respir Dis. 1979 Aug;120(2):337-43. doi: 10.1164/arrd.1979.120.2.337.
Using metronidazole in oral dosages of 1.5 to 2 g daily, we treated 13 adults who had anaerobic pleuropulmonary infections, including 11 with lung abscess, one with necrotizing pneumonia, and one with thoracic empyema. Five patients (four with lung abscess and one with necrotizing pneumonia) were cured. The lung abscesses of 5 patients did not respond. For 3 patients (one with epigastric distress who refused metronidazole, one with undrained empyema, and one who died while receiving metronidazole), therapy could not be evaluated. Side effects included leukopenia (2 patients), leukopenia and neutropenia (one), neutropenia (one), dark urine (two), bitter taste (two), and epigastric distress (one). In light of our findings, metronidazole is not uniformly effective in the treatment of anaerobic pleuropulmonary infections.
我们使用每日口服剂量为1.5至2克的甲硝唑,对13名患有厌氧性胸膜肺部感染的成年人进行了治疗,其中包括11例肺脓肿患者、1例坏死性肺炎患者和1例胸腔积脓患者。5名患者(4例肺脓肿患者和1例坏死性肺炎患者)治愈。5名患者的肺脓肿没有反应。对于3名患者(1例因上腹部不适拒绝使用甲硝唑、1例胸腔积脓未引流、1例在接受甲硝唑治疗时死亡),无法评估治疗效果。副作用包括白细胞减少(2例)、白细胞减少和中性粒细胞减少(1例)、中性粒细胞减少(1例)、尿液变黑(2例)、口苦(2例)和上腹部不适(1例)。根据我们的研究结果,甲硝唑在治疗厌氧性胸膜肺部感染方面并非始终有效。